{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:54:55Z","timestamp":1792101295146,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1188,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1124\/dmd.121.000538","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T15:40:13Z","timestamp":1629733213000},"page":"919-928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation"],"prefix":"10.1016","volume":"49","author":[{"given":"Olena","family":"Anoshchenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Storelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashvant D.","family":"Unadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000538_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000538_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-018-0685-y","article-title":"Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs","volume":"58","author":"Abduljalil","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000538_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.121.000538_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2007.02.036","article-title":"Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor","volume":"339","author":"Agarwal","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.121.000538_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000538_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1124\/dmd.120.000067","article-title":"Gestational Age-Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics","volume":"48","author":"Anoshchenko","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2020.08.010","article-title":"Microphysiological systems of the placental barrier","volume":"161-162","author":"Arumugasaamy","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.121.000538_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cpt.1373","article-title":"Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics","volume":"106","author":"Billington","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000538_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0002-9378(77)90466-5","article-title":"In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta","volume":"127","author":"Blanford","year":"1977","journal-title":"Am J Obstet Gynecol"},{"key":"10.1124\/dmd.121.000538_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1310\/hct0906-418","article-title":"Pharmacokinetics, efficacy, and safety of darunavir\/ritonavir 800\/100 mg once-daily in treatment-na\u00efve and -experienced patients [published correction appears in HIV Clin Trials (2009) 10]","volume":"9","author":"Boffito","year":"2008","journal-title":"HIV Clin Trials"},{"key":"10.1124\/dmd.121.000538_bib11","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1530\/JOE-17-0402","article-title":"Trophoblast lineage specification, differentiation and their regulation by oxygen tension","volume":"236","author":"Chang","year":"2018","journal-title":"J Endocrinol"},{"key":"10.1124\/dmd.121.000538_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40262-015-0325-8","article-title":"Physiologically based modelling of darunavir\/ritonavir pharmacokinetics during pregnancy","volume":"55","author":"Colbers","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000538_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jac\/dku400","article-title":"Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women","volume":"70","author":"Colbers","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.121.000538_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jac\/dku367","article-title":"Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir\/ritonavir doses during late pregnancy","volume":"70","author":"Cressey","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.121.000538_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.taap.2012.03.008","article-title":"Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux","volume":"260","author":"Crowe","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/380799","article-title":"Once-daily versus twice-daily lopinavir\/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial","volume":"189","author":"Eron","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.121.000538_bib17","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1128\/AAC.00863-15","article-title":"Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment","volume":"59","author":"Fauchet","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.121.000538_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00126334-200406010-00001","article-title":"Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins","volume":"36","author":"Gimenez","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.121.000538_bib19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.2008.1","article-title":"Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study","volume":"84","author":"Hebert","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000538_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0026-895X(24)09249-6","article-title":"P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir","volume":"59","author":"Huisman","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/dmd.117.076539","article-title":"Successful prediction of in vivo hepatobiliary clearances and hepatic concentrations of rosuvastatin using sandwich-cultured rat hepatocytes, transporter-expressing cell lines, and quantitative proteomics","volume":"46","author":"Ishida","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib22","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1007\/s11095-016-2028-8","article-title":"Placental ABC transporters: biological impact and pharmaceutical significance","volume":"33","author":"Joshi","year":"2016","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.121.000538_bib23","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1038\/psp.2012.2","article-title":"A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction","volume":"1","author":"Ke","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib24","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bcp.12207","article-title":"Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19","volume":"77","author":"Ke","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib26","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1093\/jac\/dkq324","article-title":"Impact of drug transporters on cellular resistance towards saquinavir and darunavir","volume":"65","author":"K\u00f6nig","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.121.000538_bib27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/dmd.121.000367","article-title":"In vivo-to-in vitro extrapolation of transporter-mediated renal clearance: relative expression factor versus relative activity factor approach","volume":"49","author":"Kumar","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/dmd.118.082313","article-title":"The Importance of incorporating OCT2 plasma membrane expression and membrane potential in IVIVE of metformin renal secretory clearance","volume":"46","author":"Kumar","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib29","doi-asserted-by":"crossref","first-page":"R963","DOI":"10.1152\/ajpregu.00173.2005","article-title":"P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages","volume":"289","author":"Mathias","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/dmd.121.000538_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.placenta.2005.12.010","article-title":"Metabolism of synthetic steroids by the human placenta","volume":"28","author":"Murphy","year":"2007","journal-title":"Placenta"},{"key":"10.1124\/dmd.121.000538_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3291","article-title":"Therapeutic drug monitoring of darunavir\/ritonavir in pregnancy","volume":"24","author":"Murtagh","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.121.000538_bib32","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1517\/17425250903304049","article-title":"Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues","volume":"5","author":"Myllynen","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000538_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/17425255.3.3.331","article-title":"The fate and effects of xenobiotics in human placenta","volume":"3","author":"Myllynen","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000538_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(99)00008-3","article-title":"The expression and regulation of drug metabolism in human placenta","volume":"38","author":"Pasanen","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.121.000538_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00563006","article-title":"The placental transfer of betamethasone","volume":"18","author":"Petersen","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/cpt.72","article-title":"The concept of fraction of drug transported (ft ) with special emphasis on BBB efflux of CNS and antiretroviral drugs","volume":"97","author":"Prasad","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000538_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"},{"key":"10.1124\/dmd.121.000538_bib38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1124\/dmd.120.000156","article-title":"Successful prediction of positron emission tomography-imaged metformin hepatic uptake clearance in humans using the quantitative proteomics-informed relative expression factor approach","volume":"48","author":"Sachar","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/1471-0528.14151","article-title":"The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy","volume":"124","author":"Scaffidi","year":"2017","journal-title":"BJOG"},{"key":"10.1124\/dmd.121.000538_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1124\/dmd.121.000538_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0091270012445205","article-title":"Steadystate pharmacokinetics of etravirine and lopinavir\/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers","volume":"53","author":"Sch\u00f6ller-Gy\u00fcre","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib941","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11530690-000000000-00000","article-title":"Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment","volume":"49","author":"Sekar","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000538_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2125.2008.03191.x","article-title":"Pharmacokinetics of darunavir\/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers","volume":"66","author":"Sekar","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 7","key":"10.1124\/dmd.121.000538_bib43","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1093\/cid\/ciu709","article-title":"Designing drug trials: considerations for pregnant women","volume":"59","author":"Sheffield","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.121.000538_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0000000000000668","article-title":"Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women","volume":"70","author":"Stek","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.121.000538_bib45","doi-asserted-by":"crossref","unstructured":"Storelli F, Anoshchenko O, Unadkat JD (2021) Successful prediction of human brain Kp,uu of P-gp substrates using the proteomics-informed relative expression factor approach. Clin Pharmacol Ther 10.1002\/cpt.2227.","DOI":"10.1002\/cpt.2227"},{"key":"10.1124\/dmd.121.000538_bib46","doi-asserted-by":"crossref","unstructured":"Storelli F, Billington S, Kumar AR, Unadkat JD (2020) Abundance of P-glycoprotein and other drug transporters at the human blood-brain barrier in Alzheimer\u2019s disease: a quantitative targeted proteomic study. Clin Pharmacol Ther 10.1002\/cpt.2035.","DOI":"10.1002\/cpt.2035"},{"key":"10.1124\/dmd.121.000538_bib47","first-page":"405","article-title":"Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement","volume":"70","author":"Tayrouz","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000538_bib48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.xphs.2015.12.005","article-title":"Insights from an integrated physiologically based pharmacokinetic model for brain penetration","volume":"105","author":"Trapa","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000538_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.118.083279","article-title":"In vitro-in vivo extrapolation of key transporter activity at the blood-brain barrier","volume":"47","author":"Trapa","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/clpt.1980.136","article-title":"Disporition of synthetic glucocorticoids. II. Dexamethasone in parturient women","volume":"28","author":"Tsuei","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000538_bib51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/jpet.111.184200","volume":"339","author":"Uchida","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000538_bib52","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.114.214536","article-title":"Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys","volume":"350","author":"Uchida","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000538_bib53","doi-asserted-by":"crossref","first-page":"24248","DOI":"10.1016\/S0021-9258(18)35757-0","article-title":"Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone","volume":"267","author":"Ueda","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000538_bib54","unstructured":"US Food and Drug Administration (2017). In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies: Guidance for Industry (FDA). Silver Spring, MD."},{"key":"10.1124\/dmd.121.000538_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib56","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jcph.936","article-title":"Physiologically based pharmacokinetic modeling for predicting the effect of intrinsic and extrinsic factors on darunavir or lopinavir exposure coadministered with ritonavir","volume":"57","author":"Wagner","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000538_bib57","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.114.062984","article-title":"Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes","volume":"43","author":"Zhang","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib58","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/dmd.117.075192","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000538_bib59","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/dmd.116.073957","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:51:52Z","timestamp":1740037912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0090955624080188"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000538","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s)","name":"copyright","label":"Copyright"}]}}